Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oramed Pharmaceuticals Inc. [ORMP] stock Initiated by Canaccord Genuity analyst, price target now $27
https://dbtnews.com/2022/02/03/oramed-pharmaceuticals-inc-ormp-stock-initiated-by-canaccord-genuity-analyst-price-target-now-27/
There are multiple variables that are factors:
• Rising Inflation
• The Omicrom variant
• The continuing chip shortage
• Shortages on the shelves due to shipping problems and vacant jobs
• The possibilities of Russia invading the Ukraine and China invading Taiwan.
• And a couple weeks of all the financial markets getting hammered is scaring a bunch of people to sell their stocks.
(January 15, 2022) Zacks Investment Research upgraded shares of AVITA Medical (NASDAQ:RCEL) from a hold rating to a buy rating in a research note released on Tuesday, Zacks.com reports. They currently have $13.00 price target on the stock.
Why Joe Biden Nominee Dr. Robert Califf Would Be A Pro-Patient FDA Head
https://www.ibtimes.com/why-joe-biden-nominee-dr-robert-califf-would-be-pro-patient-fda-head-3358634
I found this on SeekingAlpha:
JP Morgan Healthcare Conference Presentation
https://hotcopper.com.au/threads/ann-jp-morgan-healthcare-conference-presentation.6526016/?post_id=58772384
I wonder if the presenation will eventually get released so we can all see it.
AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
https://seekingalpha.com/pr/18620963-avita-medical-establishes-proof-of-concept-for-novel-treatments-using-genetically-modified
That story announced their first patient enrolled in the trial. That doesn't mean that they stopped accepting others. For all we know, the trial is filled up with the 24 subjects and they currently in the middle of trial and collecting data.
Didn't Kidron mention in an interview that covid held up the start time of the human trial?
You forget that about 35% of the population are afraid of needles. Thirty five percent of 8 billion people is a very healthy addressable market and the idea of abandoning this path in the middle of the trial is frankly idiotic. Just in America alone, there are about 19 MILLION unvaccinated people that would get vaccinated if it came in pill form.
That vaccine only targets one protein, the spike protein, the same as the other vaccines currently on the market. The spike protein is the one that mutates into new variants of the virus. The omicron variant of the virus has about 50 genetic mutations, with 36 of them in the spike protein.
The pill that Oravax is developing targets three different proteins, which is supposed to provide much better protection against new mutated variants of the virus. And again, if the Oravax tech works, it can be easily adapted to other protein-based vaccines like the yearly flu jab for example. New revenue streams would be a great for the stock price.
Oravax inks oral COVID-19 vaccine supply deal amid talks about public listing
https://www.fiercepharma.com/drug-delivery/oravax-inks-oral-covid-19-vaccine-supply-deal-amid-talks-about-public-listing
Don't forget that the Mexican pharmaceutical company that Oramed partnered with produces meds for 21 countries in Latin American. I also think that they were going to help Oramed get through the red tape with the government when they do a phase 2 trial over there.
Why would they stop now? They are already in human trials and with their partnerships in Mexico and Asia, they could probably get emergency use approval by June. Also, if the tech works, they could easily adapt it to other virus-based vaccines...the yearly flu jab for example. They would be leaving easy money on the table.
If I remember correctly, there were 10 people in the expanded access protocol. Too bad it's not for everyone that participated in the phase 3 trial. That would be a lot of additional data that could have been useful to help push for FDA approval.
This week, Biden will be signing the ACT for ALS bill into law.
There were 331 in the House & 64 in the Senate that sponsored the bill.
From the Facebook No More Excuses ALS Watchdog Group:
NurOwn Benefits Patients With Less Severe ALS, Analyses Show
https://alsnewstoday.com/news-posts/2021/12/17/nurown-benefits-patients-less-severe-als-analyses-show/
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo
https://seekingalpha.com/pr/18603001-avita-medical-completes-enrollment-in-pivotal-trial-evaluating-recell-system-for
Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright
https://www.tipranks.com/news/blurbs/oramed-pharmaceuticals-ormp-receives-a-buy-from-h-c-wainwright/
As I understand it, the bill does not benefit Nurown. After the bill passes though, No More Excuses ALS will shift their focus towards getting the FDA to pass Nurown.
SENATE LIST (Updated Dec. 15th) 62 Total sponsors
Don't know but all the financial markets are in the red today again...that could be a factor.
Kinda surprised that the stock did not spike dramatically with that news.
https://twitter.com/stevens_nation/status/1469699165991047168/photo/1
When I started the phase 3 #NurOwn trial I was rapidly declining, using a cane and bipap. A year later I was cane and bipap free. Today I remain bipap free but my progression has now returned with vengeance! #nurownworks #phase4 #christmas #wishlist pic.twitter.com/uSXgFr4plQ
— ALS Uncensored 🏴☠️ (@ScottsFight) December 11, 2021
The bill has passed in the Congress!
They are currently talking about the bill on the house floor:
https://live.house.gov/?date=2021-12-08&fbclid=IwAR2RK0g25_buDzdRDnW8R-_A23VztP28Q6sXIRCn_5aOCCq1pZlnebz6LV4
They start talking about it at 4:12:54.